Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific

MISSISSAUGA, Ontario and MELBOURNE, Australia, March 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix^®), a life sciences innovator, manufacturer, and exporter, and the Australian Centre for the Prevention of Cervical Cancer (ACPCC) with its Australian HPV Reference Laboratory, announce that they have signed a Memorandum Of Understanding (MOU) under which Microbix will supply its PROCEEDx™FLOQ^® brand Quality Assessment Products (QAPs™) to support quality management of testing for high-risk Human Papillomavirus (HPV) infections, which cause most cases of cervical cancer. The MOU signing took place in Microbix’s exhibition booth at the 30^th annual congress of the European Research Organization on Genital Infection and Neoplasia (EUROGIN 2025) in Porto, Portugal (March 16-19 2025).

Read more at globenewswire.com